There’s no question however that the latest result further diminishes the prospects for IL-6 inhibitors as a coronavirus therapy. The hypothesis behind the use of the drugs is that they ...

UK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 inhibitor will succeed ... is an IL-6 inhibiting drug that was originally developed ...

Drug development researchers have continued ... of tumor necrosis factor (TNF), interleukin (IL)-6, and IL-1. 1 Early-generation p38 inhibitors (for example, BIRB796 and SCIO469) showed only ...

The drug will be available in both intravenous and subcutaneous injections, with the same formulation and dosages as the ...

For the rest, JAK inhibitors were the most common (1,827 patients; 82% baricitinib [Olumiant]), followed by rituximab (n=1,149), abatacept (n=1,102), and anti-IL-6 drugs (n=887, 80% tocilizumab).